- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05168826
China S3 PMS: SAPIEN 3 China Post Market Registry Study
October 30, 2023 updated by: Edwards Lifesciences
SAPIEN 3 China Post Market Registry Study
The objective of this study is to evaluate the long term safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve system in real world setting.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an observational, single-arm, multicentre, post-market study.
Study Type
Observational
Enrollment (Estimated)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Edwards THV Clinical Affairs
- Phone Number: 949-250-2500
- Email: THV_CT.gov@Edwards.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Peking University Third Hospital
-
-
Fujian
-
Xiamen, Fujian, China, 361004
- Recruiting
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- First affiliated Hospital of Sun Yat-Sen University
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, China, 450000
- Recruiting
- Henan Provincial Chest Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Recruiting
- The Second Xiangya Hospital of Central South University
-
-
Shangahi
-
Shanghai, Shangahi, China, 200000
- Recruiting
- Shanghai General Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Shanghai Chest Hospital
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
-
Shanxi
-
Xi'an, Shanxi, China, 710000
- Recruiting
- The First Affiliated Hospital of Xi'an Jiao Tong University
-
-
Xinjiang Province
-
Ürümqi, Xinjiang Province, China, 830000
- Recruiting
- First Affiliated Hospital of Xinjiang Medical University
-
Ürümqi, Xinjiang Province, China, 830000
- Recruiting
- People's Hospital of Xinjiang Uygur Autonomous Region
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Subjects who will undergo TAVI with the Edwards SAPIEN 3 System.
Description
Inclusion Criteria:
- Patient with symptomatic, severe, calcified aortic stenosis who is appropriate for the treatment with transcatheter aortic valve replacement as determined by a heart team and will undergo TAVI with the Edwards SAPIEN 3 System as part of standard-of-care treatment
- All surgical risks as determined by the site Heart Team
- The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.
Exclusion Criteria:
- Medical, social, or psychological conditions that preclude appropriate consent and follow-up, including subjects under guardianship
- Considered to be part of a vulnerable population
- Pre-existing mechanical or bioprosthetic aortic valve
- Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
- Cannot tolerate an anticoagulation/antiplatelet regimen
- Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis
- Tortuous or calcified vessels that would prevent safe entry of the dilators and sheath
- Participating in a drug or device study that has not reached its primary endpoint
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Transcatheter Aortic Valve Implantation (TAVI)
|
Implantation of the SAPIEN 3 valve
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 10 years
|
The number of patients that died
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2022
Primary Completion (Estimated)
December 1, 2035
Study Completion (Estimated)
December 1, 2035
Study Registration Dates
First Submitted
December 10, 2021
First Submitted That Met QC Criteria
December 10, 2021
First Posted (Actual)
December 23, 2021
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis, Severe
-
Yonsei UniversityRecruitingSevere Aortic Stenosis or Severe Aortic RegurgitationKorea, Republic of
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Ceric SàrlEuropean Cardiovascular Research Center; Biosensors InternationalNot yet recruitingAortic Stenosis, Severe
-
Yonsei UniversityRecruiting
-
Edwards LifesciencesCompletedSevere Aortic StenosisSpain, Italy, Canada, Belgium, Greece, Germany, Austria, United Kingdom, Finland, Denmark, France, Switzerland, Israel, Poland, South Africa, Czechia, Netherlands, Norway
-
Second Affiliated Hospital, School of Medicine,...RecruitingSevere Aortic StenosisChina
-
Azienda Usl di BolognaUniversità degli Studi di Ferrara; University Hospital of Ferrara; Azienda Unità...RecruitingAortic Stenosis, SevereItaly
-
Edwards LifesciencesRecruitingAortic Stenosis, SevereUnited States, Australia, New Zealand, Canada
-
Thubrikar Aortic Valve, Inc.KCRIRecruitingSevere Aortic StenosisPoland
Clinical Trials on SAPIEN 3 Transcatheter Heart Valve
-
Edwards LifesciencesCompletedAortic Valve DiseaseUnited Kingdom, France, Germany, Italy, Canada
-
The Society of Thoracic SurgeonsAmerican College of CardiologyCompletedSevere Symptomatic Aortic Stenosis
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
University Health Network, TorontoUnknownThoracic Aortic Aneurysm | Stroke, Complication | Aortic Stenosis SymptomaticCanada
-
Edwards LifesciencesCompletedAortic Valve StenosisGermany, France, United Kingdom, Belgium
-
Edwards LifesciencesActive, not recruitingHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve DiseaseUnited States, Australia, Brazil
-
University of California, Los AngelesCompletedEisenmenger SyndromeUnited States
-
University Hospital Inselspital, BerneCompletedAortic Valve StenosisNetherlands, Germany, Switzerland, United Kingdom
-
Edwards LifesciencesCompletedCritical Aortic StenosisUnited States, Canada, Germany
-
Edwards LifesciencesCompletedPulmonary Valve Insufficiency | Pulmonary Regurgitation | Pulmonary Stenosis | Dysfunctional RVOT Conduit | Pulmonary ObstructionUnited States